Search clinical trials for: HAT1

Total 692 results

POZEN

Completed

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

Migraine Headaches

United States
All India Institute of Medical Sciences, Bhubaneswar

Recruiting

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

Schizophrenia

India
Consorcio Centro de Investigación Biomédica en...
Instituto de Salud Carlos III

Not yet recruiting

Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (SchizOMICS)

Diabetes | Schizophrenia | Lipid Metabolism Disorders | NAFLD | Psychosis | Treatment-resistant Schizophrenia | Side Effect
Noam Soreni

Withdrawn

Vortioxetine for the Treatment of Hoarding Disorder

Hoarding Disorder

Canada
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Schizophrenia | Bipolar I Disorder

United States
First Affiliated Hospital of Zhejiang University
Zhejiang University

Completed

Vortioxetine Adjunctive Treatment in Bipolar Depression (Vortioxetine)

Bipolar Depression

China
Seasons Biotechnology (Taizhou) Co., Ltd.

Completed

Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Major Depressive Disorder (MDD)

India
Ain Shams University

Completed

Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy

Analgesia | Anesthesia | Hysterotomy

Egypt
University of Medicine and Dentistry of New Jersey

Completed

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children (Abilify)

Autism

United States
University of Copenhagen

Completed

Pan European Collaboration on Antipsychotic Naïve Schizophrenia II (PECANSII)

Schizophrenia

Denmark
Chonbuk National University Hospital
Otsuka Pharmaceutical Co., Ltd.

Completed

Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients

Schizophrenia

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

Schizophrenia

Japan
Kettering Health Network

Terminated

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia (BEST)

Schizophrenia

United States
Fundación Marques de Valdecilla
Centro de Investigación Biomédica en Red de Salud Mental; Instituto de Investigación...

Unknown

Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up (PAFIP3_1Y)

Psychotic Disorders | Schizophrenia

Spain
Danish Headache Center

Completed

The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects

Headache

Denmark
Medical University of South Carolina

Completed

Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) (BAART)

Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

Schizophrenia

United States
Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Unknown

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Bioequivalence

China
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

Schizophrenia

Japan
GlaxoSmithKline

Completed

A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.

Migraine Disorders

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

Autistic Disorder

Japan
Craig Rush
National Institute on Drug Abuse (NIDA)

Completed

Aripiprazole to Reduce Cocaine Relapse

Cocaine-Related Disorders

United States
GlaxoSmithKline

Completed

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

Migraine, Without Aura

United States
GlaxoSmithKline

Completed

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

Migraine Disorders

United States
Northwell Health
National Institute of Mental Health (NIMH)

Completed

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

Schizophrenia

United States
St. Luke's-Roosevelt Hospital Center
Bristol-Myers Squibb

Completed

Abilify as an Adjunctive Treatment for Refractory Depression

Depressive Disorder, Major

United States
Sanofi

Completed

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Colorectal Neoplasms | Colorectal Carcinoma | Metastases

United States, Canada, Brazil, Poland, Australia, Germany, Italy, Portugal, Spain, Argentina, Hungary, United Kingdom, Chile
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia (STEP 203)

Schizophrenia

United States, Croatia, Serbia, Bulgaria, India, Korea, Republic of, Philippines, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
University of Oxford
National Institute for Health Research, United Kingdom

Completed

Aripiprazole and Prolactin Study (APS)

Hyperprolactinemia

United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Nervous System Diseases | Schizophrenia | Mental Disorder | Bipolar 1 Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Schizophrenia

France, South Africa, Canada, Russian Federation, Poland, Czech Republic, Hungary, Croatia, Netherlands, Romania, United Kingdom
University Hospitals Cleveland Medical Center
Bristol-Myers Squibb

Completed

Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

Schizophrenia

United States
Indiana University School of Medicine
Bristol-Myers Squibb

Completed

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

Asperger's Disorder | Pervasive Developmental Disorder

United States
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

Major Depressive Disorder
University of North Carolina, Chapel Hill
Bristol-Myers Squibb

Completed

Study of Aripiprazole to Treat Children and Adolescents With Autism (PAIRS)

Autism Spectrum Disorder | Autistic Disorder | Asperger Syndrome

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder

Taiwan, Korea, Republic of, Japan, China
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder

Taiwan, Korea, Republic of, Japan, China
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

Dementia, Alzheimer Type
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Subjects With Alcoholism

Alcoholism

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder | Psychotic Disorder | Body Weight Change

United States, Brazil, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Parkinson's Disease | Psychoses

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Oral Acceptability Trial

Schizophrenia

United States
The University of Texas Health Science Center at...
Bristol-Myers Squibb

Completed

Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

Schizoaffective Disorder | Schizophenia Disorder

United States
Juan A. Arnaiz

Unknown

ARIpiprazole in Anorexia NErvosa (ARIANE)

Anorexia Nervosa

Spain
University of Malaya

Completed

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome

Schizophrenia

Malaysia
Pfizer

Completed

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

Schizophrenia

United States, India, Russian Federation, Ukraine

Search clinical trials for: HAT1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations